Nuclear Cardiology Market Size, Share, and Growth Forecast 2026 - 2033

The global nuclear cardiology market is likely to be valued at US$ 2.90 billion in 2026 and is expected to reach US$ 4.60 billion by 2033, growing at a CAGR of 6.8% during the forecast period from 2026 to 2033. This trajectory reflects a structural shift in cardiac diagnostics: myocardial perfusion imaging and radionuclide ventriculography are moving from supplementary tests toward first-line risk stratification tools.

The American Society of Nuclear Cardiology (ASNC) has reinforced this shift through updated appropriate-use criteria, broadening the clinical indications under which myocardial perfusion imaging is reimbursed.

Driver- Rising Cardiovascular Disease Burden and Expanding Clinical Indications for Myocardial Perfusion Imaging

The World Health Organization (WHO) estimates that cardiovascular diseases account for approximately 17.9 million deaths annually, representing 32% of all mortality. This epidemiological pressure is directly translating into higher procedural volumes across nuclear cardiology departments. Specifically, myocardial perfusion imaging the cornerstone technique of the nuclear cardiology sector is increasingly deployed for pre-operative cardiac risk assessment, post-revascularization monitoring, and heart failure staging.

Academic cardiac centers such as Cleveland Clinic and Mayo Clinic have expanded their cardiac PET and SPECT imaging protocols since 2023, adding absolute myocardial blood flow quantification to standard perfusion assessments. Broader reimbursement coverage under U.S. Centers for Medicare & Medicaid Services (CMS) payment schedules has reinforced procedural uptake, particularly for high-sensitivity rubidium-82 PET perfusion studies.

Restraint- Radiation Exposure Concerns and Competition from Non-Ionizing Imaging Modalities

Nuclear cardiology procedures expose patients to ionizing radiation, a clinical consideration that affects both physician referral behavior and patient acceptance. Competing modalities specifically cardiac magnetic resonance imaging and stress echocardiography carry no radiation burden and are now endorsed by the European Society of Cardiology (ESC) for functional cardiac assessment. As cardiac MRI scanner availability improves in tertiary centers, some nuclear cardiology referrals, particularly lower-complexity stress tests, face substitution pressure.

Opportunity- AI-Assisted Image Interpretation and Workflow Automation

Artificial intelligence integration into nuclear cardiology image analysis represents the most significant near-term value expansion opportunity in this space. Siemens Healthineers launched its AI-Rad Companion Cardiac suite incorporating SPECT quantification capabilities in 2023, enabling automated segmental wall motion analysis and perfusion scoring. Hospitals adopting AI-assisted reading workflows report measurable reductions in physician interpretation time and inter-reader variability.

For healthcare systems managing radiologist shortages a documented structural challenge per Association of American Medical Colleges (AAMC) workforce projections AI augmentation directly improves throughput without proportional staffing increases. This creates a capital investment narrative that resonates across both developed and emerging market buyers.

Product Type Insights

Why Does SPECT Continue to Dominate the Market?

SPECT accounts for 47.0% of the nuclear cardiology market in 2026, equivalent to US$ 1.36 billion. SPECT maintains this commanding position because its installed base is vast, its operational costs are lower than PET, and the technical expertise required for myocardial perfusion imaging with Tc-99m agents is widely distributed across community hospital nuclear medicine departments. Cardiologists at mid-tier regional hospitals routinely use SPECT for exercise and pharmacological stress testing in patients presenting with stable chest pain, making it the workhorse of outpatient cardiac risk stratification globally.

PET is the fastest-growing segment, propelled by flurpiridaz F-18's clinical advancement and the superior attenuation correction and absolute quantification it enables. GE HealthCare has actively expanded its dedicated cardiac PET scanner portfolio, and several U.S. academic medical centers added cardiac PET programs between 2023 and 2025 specifically to leverage improved diagnostic accuracy in obese patients a population where SPECT image quality degrades meaningfully.

Application Insights

What Is Driving Coronary Artery Disease's Dominance in Nuclear Cardiology Procedures?

Coronary Artery Disease (CAD) accounts for 38.0% of the nuclear cardiology market in 2026, equivalent to US$ 1.10 billion. CAD dominates because myocardial perfusion imaging is the established, guideline-endorsed method for non-invasive ischaemia detection in patients with known or suspected obstructive coronary artery disease. Interventional cardiologists at high-volume centers such as those within the Johns Hopkins Health System rely on pre-procedural SPECT data to guide revascularization decisions and define the territory of at-risk myocardium before stenting or bypass surgery.

Cardiomyopathy is the fastest-growing application segment, driven by the emergence of technetium-99m pyrophosphate scintigraphy as the definitive non-invasive diagnostic for transthyretin amyloid cardiomyopathy (ATTR-CM). Pfizer's tafamidis approval by the U.S. Food and Drug Administration (FDA) in 2019 created a treatment pathway, and confirmed ATTR-CM diagnosis now requires nuclear scintigraphy per international consensus guidelines, generating a structurally new and expanding referral stream that did not exist at scale five years ago.

 

North America Nuclear Cardiology Market Trends

North America accounts for 35.0% of the global market in 2026, representing US$ 1.01 billion. The region's leadership reflects a convergence of mature reimbursement infrastructure, high cardiovascular disease prevalence, and concentrated academic cardiac imaging expertise. CMS reimbursement frameworks for myocardial perfusion imaging remain among the most comprehensive globally, sustaining consistent procedural volumes. Continued AI integration and cardiac PET expansion at academic health systems will reinforce North America's structural lead through 2033.

U.S. Nuclear Cardiology Market Trends

The U.S. represents 88.0% of the North America market in 2026, equivalent to US$ 0.89 billion. Demand is anchored by the country's 84 million adults aged 55 and older the primary demographic for cardiac risk stratification alongside a dense network of hospital-based nuclear medicine departments. Accelerating adoption of dedicated cardiac PET scanners and AI-assisted perfusion analysis positions the U.S. market for above-average growth within the region through 2033.

Canada Nuclear Cardiology Market Trends

Canada represents 12.0% of North America in 2026, equivalent to US$ 0.12 billion. Publicly funded health systems in Ontario and British Columbia have steadily expanded myocardial perfusion imaging capacity within academic cardiac centers. The Canadian Institutes of Health Research (CIHR) continues funding cardiovascular diagnostic research, supporting a pipeline of clinical evidence that should underpin incremental reimbursement expansion for advanced nuclear cardiology procedures.

Europe Nuclear Cardiology Market Trends

Europe accounts for 21.0% of the global market in 2026, representing US$ 0.61 billion. The European Association of Nuclear Medicine (EANM) drives protocol standardization across member states, creating a relatively harmonized regulatory and clinical environment. National reimbursement heterogeneity remains a friction point, but the ESC 2023 guidelines' stronger endorsement of myocardial perfusion imaging for stable coronary artery disease assessment is progressively lifting referral rates across Western European markets.

Germany Nuclear Cardiology Market Trends

Germany represents 37.0% of the Europe market in 2026, equivalent to US$ 0.23 billion. Germany's densely networked university hospital system anchored by institutions such as Charité – Universitätsmedizin Berlin generates high procedural volumes in nuclear cardiology, supported by the Gemeinsamer Bundesausschuss (G-BA) reimbursement framework. Ongoing investment in hybrid SPECT/CT and PET/CT systems points toward continued equipment-led market expansion through 2033.

U.K. Nuclear Cardiology Market Trends

The U.K. represents 15.0% of Europe in 2026, equivalent to US$ 0.09 billion. The National Health Service (NHS) England's cardiac diagnostics recovery program, launched post-pandemic to address a significant elective procedure backlog, has directed capital toward nuclear medicine department capacity. As waiting-list reduction targets drive throughput investment, nuclear cardiology procedure volumes within NHS Trusts are expected to grow through the forecast period.

Which Region Will Drive the Fastest Nuclear Cardiology Market Growth Through 2033?

Asia Pacific accounts for 28.0% of the global market in 2026, representing US$ 0.81 billion, and is the fastest-growing region at an estimated CAGR of 7.2%. Cardiovascular disease incidence is rising sharply across the region's ageing populations, and national health authorities are committing infrastructure investment at scale. Regional expansion of cyclotron networks and radio pharmacy distribution hubs particularly in China, Japan, and South Korea is resolving the tracer supply constraints that historically limited cardiac PET uptake outside major urban centers.

China Nuclear Cardiology Market Trends

China represents 30.0% of Asia Pacific in 2026, equivalent to US$ 0.24 billion. The National Medical Products Administration (NMPA) has accelerated regulatory review timelines for diagnostic radiopharmaceuticals, enabling faster market entry for novel PET tracers. As the National Health Commission of China continues certifying nuclear medicine departments at provincial hospitals, procedural capacity and consequently equipment and tracer demand will expand substantially through 2033.

India Nuclear Cardiology Market Trends

India represents 22.0% of Asia Pacific in 2026, equivalent to US$ 0.18 billion. The Board of Radiation and Isotope Technology (BRIT), operating under the Department of Atomic Energy, supplies Tc-99m generators to hospitals nationally, providing a government-backed supply chain that differentiates India from other emerging markets reliant on imported isotopes. Expansion of private cardiac hospital chains, including Narayana Health and Fortis Healthcare, is steadily broadening the urban nuclear cardiology installed base.

 

The nuclear cardiology market is moderately consolidated at the equipment tier and more fragmented at the radiopharmaceutical tier. GE HealthCare and Siemens Healthineers dominate SPECT and PET scanner supply globally, with Canon Medical Systems Corporation and Koninklijke Philips N.V. competing for market share in hybrid SPECT/CT systems.

The radiopharmaceutical segment features a distinct competitive dynamic: Lantheus Holdings Inc., Curium Pharma, Bracco Imaging S.p.A., and Cardinal Health Inc. compete on tracer portfolio breadth, distribution network density, and production reliability. Jubilant Radiopharma, Eckert & Ziegler Group, and Spectrum Dynamics Medical occupy specialist positions in production infrastructure and dedicated cardiac SPECT systems respectively.

Key Industry Developments:

• In March 2025, GE HealthCare launched Flyrcado (flurpiridaz F 18) injection in select U.S. markets, introducing a new positron emission tomography (PET) myocardial perfusion imaging agent for detecting coronary artery disease (CAD).